LUCENTIS Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving LUCENTIS Growth

1. Large and Growing Prevalence of Retinal Diseases

One of the biggest drivers of Lucentis adoption is the rising prevalence of retinal disorders such as neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

• Age-related macular degeneration is one of the leading causes of blindness among people over 60 years old worldwide.
• The aging global population is expected to significantly increase the number of patients requiring anti-VEGF therapy over the coming decades.

Lucentis works by inhibiting vascular endothelial growth factor (VEGF-A), preventing abnormal blood vessel growth and leakage in the retina-one of the primary causes of vision loss in these diseases.

2. Multiple Approved Indications Expanding the Patient Pool

Lucentis has obtained approvals across several retinal conditions, significantly increasing its addressable market. Major indications include:

• Neovascular (wet) age-related macular degeneration
• Diabetic macular edema
• Macular edema following retinal vein occlusion
• Diabetic retinopathy

Earlier approvals in additional indications helped expand utilization beyond AMD and drove strong early sales growth globally.

The broad label allows ophthalmologists to prescribe Lucentis across multiple retinal diseases, supporting continued clinical demand.

3. Proven Clinical Efficacy and Physician Trust

Lucentis is one of the earliest anti-VEGF biologics approved for retinal diseases and has extensive clinical evidence demonstrating its effectiveness.

Clinical trials have shown:

• Significant improvements in best-corrected visual acuity (BCVA) in wet AMD patients
• Reduced retinal fluid and improved anatomical outcomes
• Long-term safety and efficacy supported by years of real-world use

Because of this large clinical evidence base, Lucentis remains a well-established therapy in ophthalmology treatment guidelines.

4. Strong Historical Commercial Performance

Lucentis was one of the most successful ophthalmology biologics during its peak years.

• Global ranibizumab sales reached approximately $1.8 billion in 2019.
• The product continued generating meaningful revenue even in the mature stage, with $643 million in sales reported by Novartis in 2025.

Although revenues have declined due to biosimilars and competition from newer anti-VEGF therapies, Lucentis still maintains a sizable installed patient base.

5. Strong Global Commercial Infrastructure

Lucentis benefits from the combined commercialization strength of Roche/Genentech and Novartis.

Key advantages include:

• Established global ophthalmology sales networks
• Strong relationships with retina specialists and ophthalmology clinics
• Wide reimbursement coverage in major healthcare systems

6. Expansion into New Formulations and Treatment Strategies

Over time, Lucentis has been optimized to improve clinical convenience.

Key developments include:

• Prefilled syringe formulations, which reduce preparation time in clinics
• Flexible dosing strategies such as treat-and-extend regimens

These innovations improved clinical workflow and patient adherence, helping maintain market share.

LUCENTIS Recent Developments

• In December 2025, the FDA approved Nufymco as an interchangeable biosimilar to Lucentis, marking a new competitor in the US market developed by Formycon and Bioeq.

"LUCENTIS Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of LUCENTIS for approved indication like Choroidal neovascularisation, Diabetic macular oedema, Diabetic retinopathy, Retinal oedema, and Wet age-related macular degeneration in the 7MM. A detailed picture of LUCENTIS's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the LUCENTIS for approved indications. The LUCENTIS market report provides insights about LUCENTIS's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current LUCENTIS performance, future market assessments inclusive of the LUCENTIS market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of LUCENTIS sales forecasts, along with factors driving its market.

LUCENTIS Drug Summary

LUCENTIS is an FDA-approved recombinant humanized IgG1 kappa monoclonal antibody fragment antigen-binding (Fab) developed by Genentech (Roche), designed for intravitreal administration to treat retinal disorders driven by pathologic angiogenesis and vascular leakage. By binding with high affinity to all isoforms of vascular endothelial growth factor A (VEGF-A), it prevents VEGF-A interaction with its receptors VEGFR1 and VEGFR2 on endothelial cells, thereby inhibiting endothelial cell proliferation, vascular permeability, and neovascularization to improve visual acuity and reduce macular edema. Available in 0.3 mg (0.05 mL) and 0.5 mg (0.05 mL) single-use vials or prefilled syringes, it is indicated for neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), and diabetic retinopathy (DR), with dosing regimens typically involving monthly or pro re nata intravitreal injections after initial loading. The report provides LUCENTIS's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the LUCENTIS Market Report

The report provides insights into:

• A comprehensive product overview including the LUCENTIS MoA, description, dosage and administration, research and development activities in approved indication like Choroidal neovascularisation, Diabetic macular oedema, Diabetic retinopathy, Retinal oedema, and Wet age-related macular degeneration.
• Elaborated details on LUCENTIS regulatory milestones and other development activities have been provided in LUCENTIS market report.
• The report also highlights LUCENTIS's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
• The LUCENTIS market report also covers the patents information, generic entry and impact on cost cut.
• The LUCENTIS market report contains current and forecasted LUCENTIS sales for approved indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The LUCENTIS market report also features the SWOT analysis with analyst views for LUCENTIS in approved indications.

Methodology:

The LUCENTIS market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUCENTIS Analytical Perspective by DelveInsight

• In-depth LUCENTIS Market Assessment

This LUCENTIS sales market forecast report provides a detailed market assessment of LUCENTIS for approved indication like Choroidal neovascularisation, Diabetic macular oedema, Diabetic retinopathy, Retinal oedema, and Wet age-related macular degeneration in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted LUCENTIS sales data uptil 2034.

• LUCENTIS Clinical Assessment

The LUCENTIS market report provides the clinical trials information of LUCENTIS for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.

LUCENTIS Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

LUCENTIS Market Potential & Revenue Forecast

• Projected market size for the LUCENTIS and its key indications
• Estimated LUCENTIS sales potential (LUCENTIS peak sales forecasts)
• LUCENTIS Pricing strategies and reimbursement landscape

LUCENTIS Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• LUCENTIS Market positioning compared to existing treatments
• LUCENTIS Strengths & weaknesses relative to competitors

LUCENTIS Regulatory & Commercial Milestones

• LUCENTIS Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

LUCENTIS Clinical Differentiation

• LUCENTIS Efficacy & safety advantages over existing drugs
• LUCENTIS Unique selling points

LUCENTIS Market Report Highlights

• In the coming years, the LUCENTIS market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The LUCENTIS companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LUCENTIS's dominance.
• Other emerging products for Choroidal neovascularisation, Diabetic macular oedema, Diabetic retinopathy, Retinal oedema, and Wet age-related macular degeneration are expected to give tough market competition to LUCENTIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LUCENTIS in approved indications.
• Analyse LUCENTIS cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted LUCENTIS sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of LUCENTIS in approved indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of LUCENTIS? How strong is LUCENTIS's clinical and commercial performance?
• What is LUCENTIS's clinical trial status in each individual indications such as Choroidal neovascularisation, Diabetic macular oedema, Diabetic retinopathy, Retinal oedema, and Wet age-related macular degeneration and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUCENTIS Manufacturers?
• What are the key designations that have been granted to LUCENTIS for approved indications? How are they going to impact LUCENTIS's penetration in various geographies?
• What is the current and forecasted LUCENTIS market scenario for approved indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of LUCENTIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to LUCENTIS for approved indications?
• Which are the late-stage emerging therapies under development for the treatment of approved indications?
• How cost-effective is LUCENTIS? What is the duration of therapy and what are the geographical variations in cost per patient?